The conformation of the estrogen receptor directs estrogen-induced apoptosis in breast cancer: A hypothesis

Hormone Molecular Biology and Clinical Investigation

Volumn 5, Issue 1, 2011, Pages 27-34

  Maximov, Philipp ^a   Lewis Wambi, Joan S ^a   Kim, Helen R ^b   Sengupta, Surojeet ^b   Jordan, V Craig ^b,d   Curpan, Ramona F ^c  

^a FOX CHASE CANCER CENTER   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c ACADEMY OF ROMANIAN SCIENTISTS   (Romania)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

breast cancer; estrogen; estrogen receptor; tamoxifen; triphenylethylenes

Indexed keywords

EID: 85007321727     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/HMBCI.2010.047     Document Type: Article

References (28)

1. Haddow A., Watkinson JM., Paterson E. Influence of synthetic oestrogens upon advanced malignant disease. Br Med J 1944; 2:393-8.
2. Haddow A. David A. Karnofsky memorial lecture. Thoughts on chemical therapy. Cancer 1970;26:737-54.
3. Gottardis MM., Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 1988;48:5183-7.
4. Balaburski GM., Dardes RC., Johnson M., Haddad B., Zhu F., Ross EA., Sengupta S., Klein-Szanto A., Liu H., Lee ES., Kim H., Jordan VC. Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance. Int J Oncol 2010;37:387-98.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
6. Yao K., Lee ES., Bentrem DJ., England G., Schafer JI., O'Regan RM., Jordan VC. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res 2000;6:2028-36.
7. Wolf DM., Jordan VC. A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res 1993;127:23-33.
8. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes JF., Hoctin-Boes G., Houghton J., Locker GY., Tobias JS. Results of the ATAC (Arimidex, Tamoxifen., Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
9. Thurlimann B., Keshaviah A., Coates AS., Mouridsen H., Mauriac L., Forbes JF., Paridaens R., Castiglione-Gertsch M., Gelber RD., Rabaglio M., Smith I., Wardley A., Price KN., Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353: 2747-57.
10. Song RX., Mor G., Naftolin F., McPherson RA., Song J., Zhang Z., Yue W., Wang J., Santen RJ. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst 2001;93:1714-23.
11. Lewis JS., Meeke K., Osipo C., Ross EA., Kidawi N., Li T., Bell E., Chandel NS., Jordan VC. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 2005;97:1746-59.
12. Maximov PY., Lewis-Wambi JS., Jordan VC. The paradox of oestradiol-induced breast cancer cell growth and apoptosis. Curr Signal Transduct Ther 2009;4:88-102.
13. Jordan VC., MacGregor Schafer JI., Levenson AS., Liu H., Pease KM., Simons LA., Zapf JW. Molecular classification of estrogens. Cancer Res 2001;61:6619-23.
14. Bentrem D., Fox JE., Pearce ST., Liu H., Pappas S., Kupfer D., Zapf JW., Jordan VC. Distinct molecular conformations of the estrogen receptor alpha complex exploited by environmental estrogens. Cancer Res 2003;63:7490-6.
15. Maximov PY., Myers CB., Curpan RF., Lewis-Wambi JS., Jordan VC. Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen. J Med Chem 2010;53:3273-83.
16. Jordan VC., Collins MM., Rowsby L., Prestwich G. A mono-hydroxylated metabolite of tamoxifen with potent antioestro-genic activity. J Endocrinol 1977;75:305-16.
17. MacGregor Schafer J., Liu H., Bentrem DJ., Zapf JW., Jordan VC. Allosteric silencing of activating function 1 in the 4-hydroxy-tamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res 2000;60: 5097-105.
18. Liu H., Lee ES., De Los Reyes A., Zapf JW., Jordan VC. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. Cancer Res 2001;61: 3632-9.
19. Lewis JS., Osipo C., Meeke K., Jordan VC. Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. J Steroid Biochem Mol Biol 2005;94:131-41.
20. Jiang SY., Wolf DM., Yingling JM., Chang C., Jordan VC. An estrogen receptor positive MCF-7 clone that is resistant to anti-estrogens and estradiol. Mol Cell Endocrinol 1992;90:77-86.
21. Sengupta S., Sharma CGN., Jordan VC. Estrogen regulation of X-box binding protein-1 and its role in estrogen induced growth of breast and endometrial cancer cells. Horm Mol Biol Clin Invest 2010;2:235-43.
22. Berman HM., Westbrook J., Feng Z., Gilliland G., Bhat TN., Weis-sig H., Shindyalov IN., Bourne PE. The protein data bank. Nucleic Acids Res 2000;28:235-42.
23. Wijayaratne AL., McDonnell DP. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists., antagonists, and selective estrogen receptor modulators. J Biol Chem 2001;276:35684-92.
24. Metivier R., Penot G., Hubner MR., Reid G., Brand H., Kos M., Gannon F. Estrogen receptor-alpha directs ordered., cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003;115:751-63.
25. Carroll JS., Liu XS., Brodsky AS., Li W., Meyer CA., Szary AJ., Eeckhoute J., Shao W., Hestermann EV., Geistlinger TR., Fox EA., Silver PA., Brown M. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005;122:33-43.
26. Shiau AK., Barstad D., Loria PM., Cheng L., Kushner PJ., Agard DA., Greene GL. The structural basis of estrogen receptor/coac-tivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998;95:927-37.
27. Pink JJ., Jordan VC. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 1996;56:2321-30.
28. Bourgoin-Voillard S., Gallo D., Laios I., Cleeren A., Bali LE., Jacquot Y., Nonclercq D., Laurent G., Tabet JC., Leclercq G. Capacity of type I and II ligands to confer to estrogen receptor alpha an appropriate conformation for the recruitment of coactivators containing a LxxLL motif-relationship with the regulation of receptor level and ERE-dependent transcription in MCF-7 cells. Biochem Pharmacol 2010;79:746-57.